Covid19-Sources

Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis investigated ivermectin in 18 randomized cl...

Bei insgesamt 36 291 Todesbescheinigungen war im Jahr 2020 laut vorläufigen Daten der Todesursachenstatistik COVID-19 als Erkrankung vermerkt. In 30 136 Fällen war dies die Todesursache, in den anderen 6 155 Fällen war es eine Begleiterkrankung. Nach diesen ersten vorläufigen Angaben des Statistischen Bundesamtes (Destatis) starben somit in 83 % dieser Fälle die betroffenen Personen an COVID-19 als sogenanntem Grundleiden, das heißt die Krankheit war die für den Tod verantwortliche Todesursache. In 17 % der Fälle starben die Personen mit COVID-19 als Begleiterkrankung, jedoch an einem anderen Grundleiden. Dies geht aus den vorläufigen Ergebnissen der Todesursachenstatistik hervor, die ab dem Berichtszeitraum Januar 2020 erstmals monatlich veröffentlicht werden und die bis zur vorliegenden Auswertung knapp 92 % aller Sterbefälle umfassen.

Dirk Brockmann Research on Complex Systems, Department of Biology, Humboldt University of Berlin, Prof. Brockmann

New data was released today regarding PIMS (MIS-C) frequency by age, severe COVID19, and severe myocarditis as a vaccine side effect. For kids, the most common issue is PIMS. More data is required to evaluate myocarditis, but it is most likely to remain small. data https://t.co/a6BhuKTuTf pic.twitter.com/nN8OgIvQBM— Yuval Harpaz (@yuvharpaz) November 4, 2021

COVID-19 Sars-CoV-2 Event Risk Assessment Planner

Vaccination reduces the risk of delta variant infection and accelerates viral clearance. Nonetheless, fully vaccinated individuals with breakthrough infections have peak viral load similar to unvaccinated cases and can efficiently transmit infection in household settings, including to fully vaccinated contacts. Host–virus interactions early in infection may shape the entire viral trajectory.

Neuinfektionen, Tote, Intensivpatienten: Sehen Sie hier, wie viele Menschen sich in Ihrer Region mit Covid-19 anstecken – täglich aktuell direkt aus den 400 Kreisen.

CDC’s home for COVID-19 data. Visualizations, graphs, and data in one easy-to-use website.

Background A cluster of over a thousand infections with the SARS-CoV-2 delta variant was identified in a predominantly fully vaccinated population in Provincetown, Massachusetts in July 2021. Immune responses in breakthrough infections with the SARS-CoV-2 delta variant remain to be defined. Methods Humoral and cellular immune responses were assessed in 35 vaccinated individuals who were tested for SARS-CoV-2 in the Massachusetts Department of Public Health outbreak investigation. Results Vaccinated individuals who tested positive for SARS-CoV-2 demonstrated substantially higher antibody responses than vaccinated individuals who tested negative for SARS-CoV-2, including 28-fold higher binding antibody titers and 34-fold higher neutralizing antibody titers against the SARS-CoV-2 delta variant. Vaccinated individuals who tested positive also showed 4.4-fold higher Spike-specific CD8+ T cell responses against the SARS-CoV-2 delta variant than vaccinated individuals who tested negative. Conclusions Fully vaccinated individuals developed robust anamnestic antibody and T cell responses following infection with the SARS-CoV-2 delta variant. These data suggest important immunologic benefits of vaccination in the context of breakthrough infections. ### Competing Interest Statement DHB is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The authors report no other conflict of interest. ### Funding Statement The authors acknowledge NIH grant CA260476, the Ragon Institute of MGH, MIT, and Harvard, the Massachusetts Consortium for Pathogen Readiness, and the Musk Foundation (D.H.B.). The authors also acknowledge the Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and Burroughs Wellcome Fund HD000849 (A.Y.C.)x. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board (IRB) of Beth Israel Deaconess Medical Center (BIDMC) gave ethical approval for this work (#2021P000344) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available in the manuscript or the supplementary material.

How do we get broad immunity to SARS-CoV-2 that will protect against future variants? 2 studies (are there more?) suggest that vaccination followed by infection gives broader protection than infection followed by vaccination. @florian_krammer @profshanecrotty @GuptaR_lab https://t.co/rqdf6rE9ej

A report published last year by the Centers for Medicare & Medicaid Services (CMS) highlighted that COVID-19 case counts are more likely to be high in lower quality nursing homes than in higher quality ones. Since then, multiple studies have examined this associa- tion with a handful also exploring the role of facility quality in explaining resident deaths from the virus. Despite this wide interest, no previous study has investigated how the relation between quality and COVID-19 mortality among nursing home residents may have changed, if at all, over the progression of the pandemic. This understanding is indeed lack- ing given that prior studies are either cross-sectional or are analyses limited to one specific state or region of the country. To address this gap, we analyzed changes in nursing home resident deaths across the US between June 1, 2020 and January 31, 2021 (n = 12,415 nursing homes X 8 months) using both descriptive and multivariable statistics. We merged publicly available data from multiple federal agencies with mortality rate (per 100,000 resi- dents) as the outcome and CMS 5-star quality rating as the primary explanatory variable of interest. Covariates, based on the prior literature, consisted of both facility- and community- level characteristics. Findings from our secondary analysis provide robust evidence of the association between nursing home quality and resident deaths due to the virus diminishing over time. In connection, we discuss plausible reasons, especially duration of staff short- ages, that over time might have played a critical role in driving the quality-mortality conver- gence across nursing homes in the US.

Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) testing, as RDTs are widely accessible and easy to use. The aim of this study was to evaluate ...

Your one-stop source on all things vaccine and COVID-19 related.

Nuvaxovid schützt nicht per RNA, sondern mithilfe von Proteinen vor Covid-19. Für seine Herstellung braucht es aber trotzdem Gentechnik. Und Impfverstärker.

Because the N protein is *inside* the actual virus, antibodies directed against the N protein cannot target viral particles. It's thought that these antibodies occur because of the rupturing of infected cells leaking N protein where a B cell might find them and become activated.

Das Rätsel von Gibraltar. Speziell die Blicke der Impfskeptiker richten sich derzeit wieder gerne nach Gibraltar. Das kleine britische Territorium an der Südspitze Spaniens hat Angaben zufolge eine Impfquote von 100 Prozent und dennoch gehen die Infektionszahlen derzeit durch die Decke. Täglich über 50 Neuinfektionen und eine 7-Tage-Inzidenz von über 1500.

Boostern oder nicht boostern: Eine große Studie zeigt, wer sich eine dritte Dosis holen sollte

Side by side event curves for the original Pfizer vaccine trial vs the Booster trial You can see the curves diverge about a week earlier with a booster, ~14 vs 7 days, which aligns with much faster induction of neutralizing antibodies https://t.co/WhnZbjyIXj

Ist eine Intensivstation voll, müssen die stabileren Schwerkranken auf Normalstationen verlegt werden. Dort steigt aber ihr Risiko, wieder intensivpflichtig zu werden. Ein gefährliches Dilemma.

In total 5,976 genomically sequenced index cases in household clusters were matched to 11,952 sporadic index cases (single case within a household). 43.3% (n=2,586) of cases in household clusters were confirmed Delta variant compared to 40.4% (n= 4,824) of sporadic cases. The odds ratio of household transmission was 1.70 among Delta variant cases (95% CI 1.48-1.95, p 0.001) compared to Alpha cases after adjusting for age, sex, ethnicity, index of multiple deprivation (IMD), number of household contacts and vaccination status of index case.

Correspondence from The New England Journal of Medicine — Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

This Medical News article discusses the stress and grief reactions that children and teens face after losing a parent or close caregiver to COVID-19.

Original Article from The New England Journal of Medicine — Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Research Square is a preprint platform that makes research communication faster, fairer, and more useful.

The durability of immune memory after SARS-CoV-2 mRNA vaccination remains unclear. Here, we longitudinally profiled vaccine responses in SARS-CoV-2 naïve and recovered individuals for 6 months afte...

24049 samples from 8858 individuals (5549 who received a second dose of ChAdOx1 and 3205 BNT162b2) who remained anti-N negative were included in the analysis of anti-S waning over time. Three weeks after the second dose of vaccine BNT162b2 mean anti-S levels were 9039 (95%CI: 7946-10905) U/ml and ChadOx1 were 1025 (95%CI: 917-1146) U/ml. For both vaccines, waning anti-S levels followed a log linear decline from three weeks after the second dose of vaccination. At 20 weeks after the second dose of vaccine, the mean anti-S levels were 1521 (95%CI: 1432-1616) U/ml for BNT162b2 and 342 (95%CI: 322-365) U/ml for ChadOx1. We identified 197 breakthrough infections and found a reduced risk of infection post second dose of vaccine for individuals with anti-S levels greater than or equal to 500 U/ml compared to those with levels under 500 U/ml (HR 0.62; 95%CIs:0.44-0.87; p=0.007). Time to reach an anti-S threshold of 500 U/ml was estimated at 96 days for ChAdOx1 and 257 days for BNT162b2. We found an increased risk of a breakthrough infection for those who received the ChAdOx1 compared to those who received BNT162b2 (OR: 1.43, 95% CIs:1.18-1.73, p0.001).

Covid-19 and its effect on the brain can be serious, researchers are learning. Studies continue to discover more on long-term Covid and how it impacts patients.

Individuals with potential exposure to SARS-CoV-2 do not necessarily develop PCR or antibody positivity, suggesting some may clear sub-clinical infection before seroconversion. T-cells can contribute to the rapid clearance of SARS-CoV-2 and other coronavirus infections1–3. We hypothesised that pre-existing memory T-cell responses, with cross-protective potential against SARS-CoV-24–11, would expand in vivo to support rapid viral control, aborting infection. We measured SARS-CoV- 2-reactive T-cells, including those against the early transcribed replication transcription complex (RTC)12,13, in intensively monitored healthcare workers (HCW) remaining repeatedly negative by PCR, antibody binding, and neutralisation (seronegative HCW, SN-HCW). SN-HCW had stronger, more multispecific memory T-cells than an unexposed pre-pandemic cohort, and more frequently directed against the RTC than the structural protein-dominated responses seen post-detectable infection (matched concurrent cohort). SN-HCW with the strongest RTC-specific T-cells had an increase in IFI27, a robust early innate signature of SARS-CoV-214, suggesting abortive infection. RNA-polymerase within RTC was the largest region of high sequence conservation across human seasonal coronaviruses (HCoV) and SARS-CoV-2 clades. RNA-polymerase was preferentially targeted (amongst regions tested) by T-cells from pre-pandemic cohorts and SN-HCW. RTC epitope-specific T-cells cross-recognising HCoV variants were identified in SN-HCW. Enriched pre-existing RNA-polymerase-specific T-cells expanded in vivo to preferentially accumulate in the memory response after putative abortive compared to overt SARS-CoV-2 infection. Our data highlight RTC-specific T-cells as targets for vaccines against endemic and emerging Coronaviridae.